Follicular Lymphoma
News
Drug receives priority review for FL
The US Food and Drug Administration (FDA) has granted priority review to a supplemental biologics license application (sBLA) for obinutuzumab (...
From the Journals
Obinutuzumab-CHOP not superior to rituximab-CHOP in new DLBCL
Two drug regimens for diffuse large B-cell lymphoma compared in a phase 3 trial.
News
Analysis reveals poor outcomes in refractory DLBCL
Results from the SCHOLAR-1 study revealed poor outcomes of salvage therapy in patients with refractory diffuse large B-cell lymphoma (DLBCL). This...
News
CHMP recommends new indication for obinutuzumab
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the marketing authorization for...
Latest News
IMiD/Anti-CD20 combo induces complete responses in r/r NHL
Lugano, Switzerland – A combination of obinutuzumab (Gazyva) and the experimental immunomodulatory agent CC-122 showed “clinically meaningful”...
Conference Coverage
Copanlisib makes inroads against relapsed/refractory follicular lymphoma
LUGANO, SWITZERLAND – New PI3K inhibitor promises better safety and efficacy for ongoing treatment.
Conference Coverage
Combo demonstrates activity in CLL/SLL and FL
LUGANO, SWITZERLAND—Results of a phase 1 study suggest a 2-drug combination may be safe and effective in patients with chronic lymphocytic...
Conference Coverage
Tazemetostat active against follicular lymphoma with EZH2 mutation
LUGANO, SWITZERLAND - Patients most likely to respond to tazemetostat were those with activating mutations in EZH2 and MYD88.
Conference Coverage
CAR T-cell therapy shows early promise in DLBCL
LUGANO, SWITZERLAND—The chimeric antigen receptor (CAR) T-cell therapy JCAR017 can produce “potent and durable” responses in patients with...
Conference Coverage
Ibrutinib/buparlisib looks good for relapsed mantle cell lymphoma
LUGANO, SWITZERLAND – The overall response rate among patients with mantle cell lymphoma in a phase I/IB dose escalation study was 100%,...
Conference Coverage
Pembrolizumab + rituximab boost response rates in relapsed follicular lymphoma
LUGANO, SWITZERLAND – The overall response rate with the combination was 65%, including 50% complete responses, in 20 patients with relapsed...